Tag: investment
-
Antibiotic Developer Adds $9.2 Million in Early Funds
3 June 2015. Auspherix Limited, a start-up developer of new antibiotic drugs, raised £6 million ($US 9.2 million) in early-stage venture financing. Funding for the two year-old enterprise, located in a pharmaceutical and biotechnology incubator at Stevenage, U.K., was led by technology commercialization company Imperial Innovations plc, with earlier investor Australia’s Medical Research Commercialisation Fund.…
-
Spin-Off Biotech Formed for Autoimmune Disorders
2 June 2015. Drug maker Astellas Pharma Inc. in Tokyo and Anokion SA, a biotechnology company in Lausanne, Switzerland, are forming Kanyos Bio Inc., a spin-off enterprise to develop therapy candidates for autoimmune diseases. The deal could bring Kanyos Bio, based in Cambridge, Massachusetts, as much as $760 million, as well as an equity investment…
-
AstraZeneca Building New Biologics Plant
18 May 2015. The pharmaceutical company AstraZeneca plans to build a new facility in Södertälje, Sweden to manufacture biologic medications. The $285 million plant is expected to employ from 150 to 250 workers when it goes into operation in 2019. Södertälje is the site of AstraZeneca’s largest factory for making tablets and capsules, as well…
-
Oxford Establishes £300M Spin-Off Capital Fund
15 May 2015. University of Oxford in the U.K. is creating a capital investment fund to help launch spin-off companies based on research from university labs. The £300 million ($US 472 million) fund will be managed by a new enterprise, Oxford Sciences Innovation plc, which will be the university’s preferred capital financier for businesses generated…
-
RNA Therapies Developer Spins-Off Rare Disease Venture
12 May 2015. Moderna Therapeutics, a developer of RNA-based treatments, is starting a new company to design therapies with its technology to address rare diseases. Financial details of the spin-off company Elpidera LLC, the third such venture launched by Moderna, were not disclosed. Moderna, a biotechnology enterprise in Cambridge, Massachusetts, develops medications that use genetic…
-
GSK, UNC Chapel Hill Partner on HIV/AIDS Cure
11 May 2015. Pharmaceutical maker GlaxoSmithKline and University of North Carolina in Chapel Hill are establishing a joint research center and spin-off company to develop new treatments for HIV and AIDS. GSK says it plans to invest $20 million over 5 years for a new HIV Cure Center on the Chapel Hill campus to conduct…
-
Heart Drug Developer Raises $46M in Venture Funds
1 May 2015. MyoKardia Inc., a developer of therapies for inherited heart diseases, raised $46 million in its second venture funding round. Taking part in the financing for the South San Francisco, California company are the drug company Sanofi that already holds an equity stake in MyoKardia, as well as venture capital firms Casdin Capital,…
-
Cancer Biotech Raising $147 Million in IPO
30 April 2015. Blueprint Medicines, a developer of cancer therapies that block enzymes supporting tumor growth, is raising some $146.7 million in its initial public stock offering. The Cambridge, Massachusetts enterprise, listed on the NASDAQ exchange under the symbol BPMC, issued 8.15 million shares at $18.00. The company began trading today with its share price…
-
Aduro Biotech Raises $108 million in IPO
15 April 2015. Aduro Biotech Inc., a developer of immunotherapies to treat cancer, issued its initial public stock offering today that expects to net the company some $108 million, after issuing 7 million shares priced at $17.00. The Berkeley, California enterprise trades on the Nasdaq exchange under symbol ADRO. As of the Nasdaq closing bell…
-
Gene Therapy Biotech Raises $60M in Venture Funds
13 April 2015. Voyager Therapeutics, a biotechnology company developing gene therapies for central nervous system disorders, raised $60 million in its second venture financing round. Financing for the 1 year-old enterprise in Cambridge, Massachusetts was led by new investors Brookside Capital and Partner Fund Management, with participation by Wellington Management Company and Casdin Capital, also…